contact us
sort news by author
Emma Petela, GK Strategy, Jamie Cater, Louise Allen, Robin Grainger,
sort news by category
Insight, Strategy, Impact,
apprenticeships, awards, B2G, Biden, Bills, Blueprint, bolt on, Boris, Boris Johnson, Brexit, business, careers, climate change, climate crisis, clinical trials, commissioning, Communications, Consumer, consumer demands, COP, covid, COVID 19, Crisis comms, culture, d, David Laws, defence, Deregulation, Devolution, Digital, Disruption, diversity, Due Diligence, economic policy, Education, elections, Energy, Energy and Environment, engagement, Environment, Equality, ESG, EU, europe, exit plan, Financial Services, general election, General News, gig economy, GK culture, gk report, Government, government affairs, Health, health & Care Bill, health and care, health and social care, health funding, health insights, Healthcare, Hendy, housing, HS2, i have a voice, infrastructure, insight, insight report, insights, integrated review, internship, Investment, Investor, Investor Backed Businesses, Investor Services, investors, Ioan, Jack Sansum, Jeremy Corbyn, job, labour conference, Labour market, Legislation, legistation, levy, life sciences, local government, lockdown, medical devices, Medicines, membership bodies, mental health, mental health services, nationalisation, NHS, no, No deal, parliament, pharma, pharmaceuticals, Planning, policy, Political Due Diligence, Politics, Pride Month, Prime Minister, Private Equity, Privatisation, Public Affairs, Public Relations, Public spending, Queen's Speech, rail, recruitment, REF, regulation, sales, Scotland, Scott, Select Committee, select committees, skills, Social Care, Spending Review, Strategic Communications, students, sustainability, Tax, Technology, The Conservative Party, The Labour Party, trade bodies, transformation, Transport, uk, UK Politics, university, US, US election, Wales, Waste, Winter Plan, women, Workplace,
Private Equity investment in Pharma – why is the UK bucking the global trend?
In recent years we’ve become used to claims that the impasse of Brexit is drying up investment in UK life sciences. The argument also goes that global investment by pharmaceuticals in R&D – predicted to grow to $181 billion by 2022 – will instead flow to other countries. There is evidence that can support this theory but if you scrape below the surface and look at investment by private equity into life sciences the picture looks quite different. The figures actually suggest that...
Artificial Intelligence: UK ‘pharmatech’ industry growth
Artificial Intelligence (AI) has been a mainstay in the public’s vocabulary for several years now. Tech revolutionaries have painted a futuristic and transformed world, if not a dystopian one; but only recently have we started to understand what this means for the ordinary citizen, such how it is transforming consumer healthcare. The ever-faster power of computer processors, the ability to house and...